- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04393090
eHealth for the Elderly (My-eStEPs)
May 13, 2020 updated by: Cankado GmbH
Multiple Myeloma Patients and Their HCPs Tested eHealth Support
Since internet usage as a complementing element in cancer care is becoming more and more important in oncological routine we launched My-eStEPs (eHealth Strategy for Elderly Patients with Multiple Myeloma) to investigate how specifically elderly patients and their Healthcare Professionals (HCPs) adopt electronic Health (eHealth) support during outpatient treatment.
The purpose of this project is to explore how eHealth support influences patients' interaction with their HCPs and how both can benefit from this.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aschaffenburg, Germany, 63739
- Hämato-Onkologische Schwerpunktpraxis
-
Eschweiler, Germany, 52249
- St.-Antonius-Hospital
-
Hamburg, Germany, 22457
- Praxis am Albertinen- Krankenhaus
-
Koblenz, Germany, 56068
- Institut fur Versorgungsforschung in der Onkologie GbR
-
Köln, Germany, 50677
- Onkologie-Köln,
-
Langen, Germany, 63225
- Gemeinschaftspraxis für Hämatologie und Onkologie
-
Neuwied, Germany, 56564
- Praxis Dr. med. Peter Ehscheidt, Facharzt für Innere Medizin, Hämatologie, Onkologie, Medikamentöse Tumortherapie und Palliativmedizin
-
Wiesbaden, Germany, 65189
- Medicum
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
30 patients (median age 75 years) suffering from multiple myeloma treated by oral IMiDs in 8 medical centers were asked to use the open eHealth platform CANKADO as a digital therapy-supporting tool.
Description
Inclusion Criteria:
- multiple myeloma patients
- treated by oral IMiDs
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of patient's internet use
Time Frame: 3 months
|
Evaluated in the following criteria: daily, at least once per week, at least once per month, less than once per month
|
3 months
|
Purpose of patient's internet use
Time Frame: 3 months
|
Evaluated in the following criteria: news, online-banking, information collection about products, health-related topics, software downloads, dictionaries
|
3 months
|
Patient's internet use for health-related topics
Time Frame: 3 months
|
Evaluated in the following criteria: does the patient use the internet for health-related topics and if yes, for what exactly
|
3 months
|
Patient's technical equipment
Time Frame: 3 months
|
The presence of following equipment was evaluated: fixed network telephone, smartphone, internet-enabled computer, notebook, laptop, iPad and tablet ownership.
|
3 months
|
eHealth usage satisfaction
Time Frame: 3 months
|
By a structured interview with the patients about their user satisfaction (graded between 1 (best) and 5 (worst))
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Timo Schinköthe, PhD, Cankado GmbH
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2016
Primary Completion (Actual)
May 1, 2017
Study Completion (Actual)
May 1, 2017
Study Registration Dates
First Submitted
May 4, 2020
First Submitted That Met QC Criteria
May 13, 2020
First Posted (Actual)
May 19, 2020
Study Record Updates
Last Update Posted (Actual)
May 19, 2020
Last Update Submitted That Met QC Criteria
May 13, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- CAN-17-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on eHealth platform CANKADO
-
iOMEDICO AGRoche Pharma AGCompletedExtensive-stage Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBCGermany
-
Göteborg UniversityRecruiting
-
Göteborg UniversityUnknown
-
Duke UniversityCompletedType 2 DiabetesUnited States
-
University of MiamiNational Institute on Drug Abuse (NIDA)CompletedDrug Use | Sexual Risk Behavior | Family FunctioningUnited States
-
Dartmouth-Hitchcock Medical CenterCompletedObesity | Videoconferencing | mHealth | Technology | Behavior, HealthUnited States
-
UKK InstituteUniversity of Eastern Finland; North Karelia Hospital DistrictUnknown
-
Dr. Danièle PacaudThe Lawson FoundationCompletedDiabetes Mellitus, Type 2Canada
-
University of Alabama at BirminghamCompletedCancer | Overweight and ObesityUnited States